Bavarian Nordic A/S: green Health Canada for examining the file of his chikungunya vaccine

Bavarian Nordic A/S announced that Health Canada has agreed to examine the request for approval of its candidate Vaccine against the single dose chikungunya. Similarly, based on viral particles (VLP), called Chikv VLP. Consequently, This request aims to immunization against the disease caused by the chikungunya virus in people aged 12 and over. For example, Acceptance of the file by management confirms that the submission of the new drug is complete. In addition, marks the start of a standard examination procedure, opening the way to a possible approval of the vaccine in the first half of 2026.

The submission is based on the same data that has already supported recent vaccine authorizations in the United States. the European Union and in the United Kingdom, in particular the results of two phase 3 clinical trials having recruited more than 3,500 healthy volunteers aged 12 and bavarian nordic a/s: green health over.

Studies have reached their main criterion: 21 days after vaccination, the vaccine induced neutralizing antibodies in up to 97.8 % of vaccinated people (97.8 % in 12-64 year olds and 87.3 % among those over 65). The key secondary criterion, the serological response rate at 8^e day after vaccination was 46.6 % and reached 96.8 % at 15^e day for 12-64 year olds, and 82.3 % at 15^e day for those over 65. Additionally, The vaccine was well tolerated, the undesirable effects linked to the vaccine being mainly of light to moderate intensity.

The most common side effects were pain in the injection site, fatigue, headache and muscle pain. Chikv VLP is intended to prevent chikungunya disease in people aged 12 and over. It is designed to induce a robust serological response, with protective immunity starting to develop in a week after vaccination.

Awaiting regulatory approval, the bavarian nordic a/s: green health VLP Chikv vaccine will be available in pre -filled syringe. Chikv VLP does not contain any viral genetic material. it is therefore non -infectious and unable to cause the disease, ensuring that a large audience can benefit from vaccination. The vaccine was approved by the American Food. Drug Administration (FDA) and the European Commission in February 2022, as well as by the United Kingdom in May 2025 under the trade name Vimkunya.